Valinor Pharma

News

Grünenthal's chief executive Gabriel Baertschi

Grünenthal buys Valinor and constipation drug for $250m

German pain medicines specialist Grünenthal has dipped another toe in the M&A waters with a $250 million agreement to buy US drugmaker Valinor Pharma.

News

Another LAG-3 setback as Regeneron drug fails phase 3 trial

Regeneron's LAG-3 inhibitor fianlimab has missed the mark in a highly anticipated melanoma trial, hitting its share price.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/register.png

Digital

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

Editor's Picks